Skip to main content
. 2018 Sep 19;27(24):4303–4314. doi: 10.1093/hmg/ddy331

Figure 5.

Figure 5

NEAT1L protects cells from mHTT-induced toxicity. (A) SH-SY5Y cells were transfected with NEAT1L-targeting or control ASOs, followed by transfection with HTT (25Q) or mHTT (104Q) expression plasmids and cell viability assessed 48 h later (n = 10 technical replicates). Data were normalized to control ASO/HTT (25Q) treated cells. Data represent mean ± SEM with significance determined by one-way ANOVA with Bonferroni post hoc comparison. **P < 0.01, ***P < 0.001, ****P < 0.000. (B) SH-SY5Y cells were transfected with NEAT1L targeting or control ASOs as described above and then 3-NP administered at the indicated doses 48 h post-transfection. Cell viability was assessed 48 h later (n = 10 technical replicates). Data are normalized to control ASO-treated groups. For each concentration, comparisons were made by Mann–Whitney two-tailed t-test. Data represent mean ± SEM, ***P < 0.001, ****P < 0.000, ns = not significant. (C) SH-SY5Y cells were co-transfected with HTT (25Q) or mHTT (104Q) expression plasmids with NEAT1L or control overexpression plasmids (n = 12 technical replicates) and cell viability assessed 48 h later. Data are mean ± SEM with significance determined by one-way ANOVA, ****P < 0.0001.